Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study to Assess the Safety and Anti-tumour Activity of Dexanabinol Monotherapy and Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours

Next Previous
Trial Profile

A Phase 1b Study to Assess the Safety and Anti-tumour Activity of Dexanabinol Monotherapy and Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexanabinol (Primary) ; Gemcitabine; Paclitaxel; Sorafenib
  • Indications Liver cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors e-Therapeutics

Most Recent Events

  • 22 Mar 2016 Status changed from recruiting to completed, according to an e-Therapeutics media release.
  • 19 May 2015 The first patient has been enrolled and has received an initial dose, according to an e-Therapeutics media release.
  • 22 Apr 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top